MedImmune signs deal with SBI Biotech
This article was originally published in Scrip
MedImmunehas signed a licensing agreement with SBI Biotechto develop and commercialise the Japanese company's anti-ILT7 protein for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. SBI will receive an up-front payment as well as milestone payments and royalties on future marketed products. MedImmune has the rights to any resulting product candidates and will be responsible for preclinical and clinical development. It will also have the option to license additional targets resulting from SBI's research activities. Dave Mott, MedImmune's ex-CEO who left the company last July, has joined New Enterprise Associates, a venture capital firm active in the biotechnology field.